

SUPPLEMENTAL FIGURE 1: Representative bladder fits for a subject. (**A**) The measured image and urine sample-derived time activity curves (TACs) for one subject and the fitted function Eq. 2 (both shown uncorrected for radioactive decay). The fitted functions extrapolated to the following voiding scenarios: complete bladder voids (**B**) every hour, (**C**) every 2 hours, and (**D**) every 4 hours post tracer administration.

Challapalli et al.



SUPPLEMENTAL FIGURE 2: Typical high-performance liquid chromatography (HPLC) chromatogram of ¹⁸F-D4-FCH and its metabolite ¹⁸F-D4-betaine in urine. Analysis of the metabolism of ¹⁸F-D4-FCH at **(A)** 90 min, **(B)** 240 min post tracer injection, shows predominant excretion of ¹⁸F-D4-betaine.

SUPPLEMENTAL TABLE 1: Comparison between ¹⁸F-D4-FCH, ¹¹C-choline and ¹⁸F-FCH

	¹¹ C-Choline *	¹¹ C-Choline†	¹⁸ F-FCH*	¹⁸ F-D4-FCH†
	(1)	(2)	(21)	(this study)
Absorbed dose (mGy/ MBq)				
Kidney	0.018	0.021	0.16	0.106
Liver	0.017	0.02	0.061	0.094
Pancreas	0.013	0.029		0.066
Urinary Bladder		0.003	0.065	0.047
Adrenals		0.004		0.046
Stomach wall		0.006		0.04
Spleen	0.008	0.009	0.055	0.038
ED (mSv/ MBq)				
	0.0028	0.0044‡	0.020‡	0.025‡
Urinary Excretion (% of injected activity)				
		2% in 1.5 h	3.4% in 1 h	4% in 1h, 6% in 2h, 7% in 4h

*Estimated using MIRDOSE †Estimated using OLINDA/EXM ‡The higher radiation dose of ¹⁸F-FCH compared to that of ¹¹C-choline is due to the longer half life of ¹⁸F

References

1. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography. *Mol Imaging Biol.* 2002;4:267-273.

2. Tolvanen T, Yli-Kerttula T, Ujula T, et al. Biodistribution and radiation dosimetry of [(11)C]choline: a comparison between rat and human data. *Eur J Nucl Med Mol Imaging.* 2010;37:874-883.

21. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. *J Nucl Med.* 2002;43:92-96.